Targeting transcriptional regulators of CD8+ t cell dysfunction to boost anti-tumor immunity

Vaccines

Volumn 3, Issue 3, 2015, Pages 771-802

  Waugh, Katherine A ^a   Leach, Sonia M ^b   Slansky, Jill E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

Anergy; Cancer immunotherapy; Exhaustion; NF B; NFAT; Pathway analysis; PD 1; T cell dysfunction; T cell hypofunction; TIL; Tolerance; Transcriptional regulation; Transcriptome analysis; Tumor infiltrating T cells

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; KRUPPEL LIKE FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 RECEPTOR; SMAD PROTEIN; SMAD3 PROTEIN; STAT PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL CYCLE G1 PHASE; DELAYED HYPERSENSITIVITY; HUMAN; IMMUNOSURVEILLANCE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 85016850583     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3030771     Document Type: Review

References (197)

1. Coley, W.B., II. Contribution to the knowledge of sarcoma. Ann. Surg. 1891, 14, 199–220.
2. Richardson, M.A.; Ramirez, T.; Russell, N.C.; Moye, L.A. Coley toxins immunotherapy: A retrospective review. Altern. Ther. Health Med. 1999, 5, 42–47.
3. Strebhardt, K.; Ullrich, A. Paul ehrlich’s magic bullet concept: 100 Years of progress. Nat. Rev. Cancer 2008, 8, 473–480.
4. Foley, E.J. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 1953, 13, 835–837.
5. Klein, G. Tumor antigens. Annu. Rev. Microbiol. 1966, 20, 223–252.
6. Old, L.J.; Boyse, E.A. Specific antigens of tumors and leukemias of experimental animals. Med. Clin. North Am. 1966, 50, 901–912.
7. Old, L.J.; Boyse, E.A. Immunology of experimental tumors. Annu. Rev. Med. 1964, 15, 167–186.
8. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The three es of cancer immunoediting. Annu. Rev. Immunol.2004, 22, 329–360.
9. Thomas, L. Discussion. In Cellular and Humoral Aspects of the Hypersensitive States; Lawrence, H.S., Ed.; Hoeber-Harper: New York, NY, USA, 1959; pp. 529–533.
10. Burnet, F.M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 1970, 13, 1–27.
11. Stutman, O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974, 183, 534–536.
12. Van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; de Plaen, E.; van den Eynde, B.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic t lymphocytes on a human melanoma. Science 1991, 254, 1643–1647.
13. Coulie, P.G.; van den Eynde, B.J.; van der Bruggen, P.; Boon, T. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat. Rev. Cancer 2014, 14, 135–146.
14. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960–1964.
15. Fridman, W.H.; Pages, F.; Sautes-Fridman, C.; Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 2012, 12, 298–306.
16. Bindea, G.; Mlecnik, B.; Tosolini, M.; Kirilovsky, A.; Waldner, M.; Obenauf, A.C.; Angell, H.; Fredriksen, T.; Lafontaine, L.; Berger, A.; et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013, 39, 782–795.
17. Reichert, T.E.; Day, R.; Wagner, E.M.; Whiteside, T.L. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998, 58, 5344–5347.
18. Naito, Y.; Saito, K.; Shiiba, K.; Ohuchi, A.; Saigenji, K.; Nagura, H.; Ohtani, H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res.1998, 58, 3491–3494.
19. Schumacher, K.; Haensch, W.; Roefzaad, C.; Schlag, P.M. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001, 61, 3932–3936.
20. Zhou, G.; Lu, Z.; McCadden, J.D.; Levitsky, H.I.; Marson, A.L. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 2004,200, 1581–1592.
21. Baitsch, L.; Fuertes-Marraco, S.A.; Legat, A.; Meyer, C.; Speiser, D.E. The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012, 33, 364–372.
22. Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013, 342, 1432–1433.
23. Galluzzi, L.; Vacchelli, E.; Bravo-San Pedro, J.M.; Buque, A.; Senovilla, L.; Baracco, E.E.; Bloy, N.; Castoldi, F.; Abastado, J.P.; Agostinis, P.; et al. Classification of current anticancer immunotherapies. Oncotarget 2014, 5, 12472–12508.
24. Zavala, V.A.; Kalergis, A.M. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015, 145, 182–201.
25. Wolchok, J.D.; Kluger, H.; Callahan, M.K.; Postow, M.A.; Rizvi, N.A.; Lesokhin, A.M.; Segal, N.H.; Ariyan, C.E.; Gordon, R.A.; Reed, K.; et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369, 122–133.
26. Zamarin, D.; Postow, M.A. Immune checkpoint modulation: Rational design of combination strategies. Pharmacol. Ther. 2015, 150, 23–32.
27. Ascierto, P.A.; Addeo, R.; Carteni, G.; Daniele, B.; de Laurentis, M.; Ianniello, G.P.; Morabito, A.; Palmieri, G.; Pepe, S.; Perrone, F.; et al. The role of immunotherapy in solid tumors: Report from the campania society of oncology immunotherapy (SCITO) meeting, Naples 2014. J. Transl. Med. 2014.
28. Barbee, M.S.; Ogunniyi, A.; Horvat, T.Z.; Dang, T.O. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann. Pharmacother. 2015, 49, 907–937.
29. Sharma, P.; Allison, J.P. The future of immune checkpoint therapy. Science 2015, 348, 56–61.
30. Whiteside, T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene2008, 27, 5904–5912.
31. Bucks, C.M.; Norton, J.A.; Boesteanu, A.C.; Mueller, Y.M.; Katsikis, P.D. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J. Immunol. 2009, 182, 6697–6708.
32. Ledford, H. Immunotherapy’s cancer remit widens. Nature 2013.
33. Macian, F.; Garcia-Cozar, F.; Im, S.H.; Horton, H.F.; Byrne, M.C.; Rao, A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002, 109, 719–731.
34. Wherry, E.J.; Ha, S.J.; Kaech, S.M.; Haining, W.N.; Sarkar, S.; Kalia, V.; Subramaniam, S.; Blattman, J.N.; Barber, D.L.; Ahmed, R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27, 670–684.
35. Baitsch, L.; Baumgaertner, P.; Devevre, E.; Raghav, S.K.; Legat, A.; Barba, L.; Wieckowski, S.; Bouzourene, H.; Deplancke, B.; Romero, P.; et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J. Clin. Investig. 2011, 121, 2350–2360.
36. Schietinger, A.; Delrow, J.J.; Basom, R.S.; Blattman, J.N.; Greenberg, P.D. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 2012, 335, 723–727.
37. Schietinger, A.; Greenberg, P.D. Tolerance and exhaustion: Defining mechanisms of T cell dysfunction. Trends Immunol. 2014, 35, 51–60.
38. Vigneron, N.; Stroobant, V.; van den Eynde, B.J.; van der Bruggen, P. Database of T cell-defined human tumor antigens: The 2013 update. Cancer Immun. 2013, 13, PMC3718731.
39. Hogquist, K.A.; Baldwin, T.A.; Jameson, S.C. Central tolerance: Learning self-control in the thymus. Nat. Rev. Immunol. 2005, 5, 772–782.
40. Mueller, D.L. Mechanisms maintaining peripheral tolerance. Nat. Immunol. 2010, 11, 21–27.
41. Buhrman, J.D.; Slansky, J.E. Improving T cell responses to modified peptides in tumor vaccines. Immunol. Res. 2013, 55, 34–47.
42. Ochsenbein, A.F.; Sierro, S.; Odermatt, B.; Pericin, M.; Karrer, U.; Hermans, J.; Hemmi, S.; Hengartner, H.; Zinkernagel, R.M. Roles of tumour localization, second signals and cross priming in cytotoxic T cell induction. Nature 2001, 411, 1058–1064.
43. Spiotto, M.T.; Yu, P.; Rowley, D.A.; Nishimura, M.I.; Meredith, S.C.; Gajewski, T.F.; Fu, Y.X.; Schreiber, H. Increasing tumor antigen expression overcomes “ignorance” to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002, 17, 737–747.
44. Bandyopadhyay, S.; Soto-Nieves, N.; Macian, F. Transcriptional regulation of T cell tolerance. Semin. Immunol. 2007, 19, 180–187.
45. Maude, S.L.; Frey, N.; Shaw, P.A.; Aplenc, R.; Barrett, D.M.; Bunin, N.J.; Chew, A.; Gonzalez, V.E.; Zheng, Z.; Lacey, S.F.; et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014, 371, 1507–1517.
46. Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; et al. Sipuleucel-t immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363, 411–422.
47. Robbins, P.F.; Morgan, R.A.; Feldman, S.A.; Yang, J.C.; Sherry, R.M.; Dudley, M.E.; Wunderlich, J.R.; Nahvi, A.V.; Helman, L.J.; Mackall, C.L.; et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29, 917–924.
48. Harris, J.E.; Bishop, K.D.; Phillips, N.E.; Mordes, J.P.; Greiner, D.L.; Rossini, A.A.; Czech, M.P. Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. J. Immunol. 2004, 173, 7331–7338.
49. Safford, M.; Collins, S.; Lutz, M.A.; Allen, A.; Huang, C.T.; Kowalski, J.; Blackford, A.; Horton, M.R.; Drake, C.; Schwartz, R.H.; et al. Egr-2 and egr-3 are negative regulators of T cell activation. Nat. Immunol. 2005, 6, 472–480.
50. Zheng, Y.; Zha, Y.; Driessens, G.; Locke, F.; Gajewski, T.F. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J. Exp. Med.2012, 209, 2157–2163.
51. Zheng, Y.; Zha, Y.; Spaapen, R.M.; Mathew, R.; Barr, K.; Bendelac, A.; Gajewski, T.F. Egr2-dependent gene expression profiling and CHiP-Seq reveal novel biologic targets in T cell anergy. Mol. Immunol. 2013, 55, 283–291.
52. DeGregori, J.; Johnson, D.G. Distinct and overlapping roles for e2f family members in transcription, proliferation and apoptosis. Curr. Mol. Med. 2006, 6, 739–748.
53. Murga, M.; Fernandez-Capetillo, O.; Field, S.J.; Moreno, B.; Borlado, L.R.; Fujiwara, Y.; Balomenos, D.; Vicario, A.; Carrera, A.C.; Orkin, S.H.; et al. Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity2001, 15, 959–970.
54. Zhu, J.W.; Field, S.J.; Gore, L.; Thompson, M.; Yang, H.; Fujiwara, Y.; Cardiff, R.D.; Greenberg, M.; Orkin, S.H.; DeGregori, J. E2F1 and E2F2 determine thresholds for antigen-induced T cell proliferation and suppress tumorigenesis. Mol. Cell. Biol. 2001, 21, 8547–8564.
55. DeRyckere, D.; DeGregori, J. E2F1 and E2F2 are differentially required for homeostasis-driven and antigen-induced T cell proliferation in vivo. J. Immunol. 2005, 175, 647–655.
56. Li, F.X.; Zhu, J.W.; Tessem, J.S.; Beilke, J.; Varella-Garcia, M.; Jensen, J.; Hogan, C.J.; DeGregori, J. The development of diabetes in e2f1/e2f2 mutant mice reveals important roles for bone marrow-derived cells in preventing islet cell loss. Proc. Natl. Acad. Sci. USA 2003, 100, 12935–12940.
57. Li, F.X.; Zhu, J.W.; Hogan, C.J.; DeGregori, J. Defective gene expression, s phase progression, and maturation during hematopoiesis in e2f1/e2f2 mutant mice. Mol. Cell. Biol. 2003, 23, 3607–3622.
58. Field, S.J.; Tsai, F.Y.; Kuo, F.; Zubiaga, A.M.; Kaelin, W.G., Jr.; Livingston, D.M.; Orkin, S.H.; Greenberg, M.E. E2f-1 functions in mice to promote apoptosis and suppress proliferation. Cell1996, 85, 549–561.
59. Zhu, J.W.; DeRyckere, D.; Li, F.X.; Wan, Y.Y.; DeGregori, J. A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection. Cell Growth Differ. 1999, 10, 829–838.
60. Lissy, N.A.; Davis, P.K.; Irwin, M.; Kaelin, W.G.; Dowdy, S.F. A common E2F-1 and p73 pathway mediates cell death induced by tcr activation. Nature 2000, 407, 642–645.
61. Intlekofer, A.M.; Takemoto, N.; Wherry, E.J.; Longworth, S.A.; Northrup, J.T.; Palanivel, V.R.; Mullen, A.C.; Gasink, C.R.; Kaech, S.M.; Miller, J.D.; et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 2005, 6, 1236–1244.
62. Pearce, E.L.; Mullen, A.C.; Martins, G.A.; Krawczyk, C.M.; Hutchins, A.S.; Zediak, V.P.; Banica, M.; DiCioccio, C.B.; Gross, D.A.; Mao, C.A.; et al. Control of effector CD8+ T cell function by the transcription factor eomesodermin. Science 2003, 302, 1041–1043.
63. Thierfelder, W.E.; van Deursen, J.M.; Yamamoto, K.; Tripp, R.A.; Sarawar, S.R.; Carson, R.T.; Sangster, M.Y.; Vignali, D.A.; Doherty, P.C.; Grosveld, G.C.; et al. Requirement for STAT4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996, 382, 171–174.
64. Ebert, P.J.; Jiang, S.; Xie, J.; Li, Q.J.; Davis, M.M. An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microrna miR-181a. Nat. Immunol. 2009, 10, 1162–1169.
65. Li, Q.J.; Chau, J.; Ebert, P.J.; Sylvester, G.; Min, H.; Liu, G.; Braich, R.; Manoharan, M.; Soutschek, J.; Skare, P.; et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007, 129, 147–161.
66. Grosso, J.F.; Kelleher, C.C.; Harris, T.J.; Maris, C.H.; Hipkiss, E.L.; de Marzo, A.; Anders, R.; Netto, G.; Getnet, D.; Bruno, T.C.; et al. Lag-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Investig. 2007, 117, 3383–3392.
67. Sun, S.C.; Chang, J.H.; Jin, J. Regulation of nuclear factor-kappab in autoimmunity. Trends Immunol. 2013, 34, 282–289.
68. Krishna, S.; Xie, D.; Gorentla, B.; Shin, J.; Gao, J.; Zhong, X.P. Chronic activation of the kinase IKKbeta impairs T cell function and survival. J. Immunol. 2012, 189, 1209–1219.
69. Clavijo, P.E.; Frauwirth, K.A. Anergic CD8+ T lymphocytes have impaired NF-kappab activation with defects in p65 phosphorylation and acetylation. J. Immunol. 2012, 188, 1213–1221.
70. Ghosh, P.; Sica, A.; Young, H.A.; Ye, J.; Franco, J.L.; Wiltrout, R.H.; Longo, D.L.; Rice, N.R.; Komschlies, K.L. Alterations in NF kappa B/Rel family proteins in splenic T cells from tumor-bearing mice and reversal following therapy. Cancer Res. 1994, 54, 2969–2972.
71. Girolomoni, G.; Ricciardi-Castagnoli, P. Dendritic cells hold promise for immunotherapy.Immunol. Today 1997, 18, 102–104.
72. Schier, W.W. Cutaneous anergy and hodgkin’s disease. N. Engl. J. Med. 1954, 250, 353–361.
73. Ashikawa, K.; Motoya, K.; Sekiguchi, M.; Ishibashi, Y. Immune response in tumor-bearing patients and animals. II. Incidence of tuberculin anergy in cancer patients. Gan 1967, 58, 565–573.
74. Barnes, S.E.; Wang, Y.; Chen, L.; Molinero, L.L.; Gajewski, T.F.; Evaristo, C.; Alegre, M.L. T cell-NF-kappab activation is required for tumor control in vivo. J. Immunother. Cancer 2015.
75. O’Shea, J.J.; Lahesmaa, R.; Vahedi, G.; Laurence, A.; Kanno, Y. Genomic views of STAT function in CD4+ T helper cell differentiation. Nat. Rev. Immunol. 2011, 11, 239–250.
76. Hirahara, K.; Poholek, A.; Vahedi, G.; Laurence, A.; Kanno, Y.; Milner, J.D.; O’Shea, J.J. Mechanisms underlying helper T cell plasticity: Implications for immune-mediated disease. J. Allergy Clin. Immunol. 2013, 131, 1276–1287.
77. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 2009, 9, 798–809.
78. Triplett, T.A.; Tucker, C.G.; Triplett, K.C.; Alderman, Z.; Sun, L.; Ling, L.E.; Akporiaye, E.T.; Weinberg, A.D. STAT3 signaling is required for optimal regression of large established tumors in mice treated with anti-OX40 and TGFbeta receptor blockade. Cancer Immunol. Res. 2015, 3, 526–535.
79. Pauken, K.E.; Wherry, E.J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015, 36, 265–276.
80. Patsoukis, N.; Brown, J.; Petkova, V.; Liu, F.; Li, L.; Boussiotis, V.A. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal. 2012.
81. Patsoukis, N.; Sari, D.; Boussiotis, V.A. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing CDC25a. Cell Cycle 2012, 11, 4305–4309.
82. Kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 2000, 6, 290–297.
83. kip1. Immunol. Lett. 2002, 81, 149–155.
84. Kip1 degradation. J. Immunol. 2002, 169, 4723–4731.
85. Kip1. J. Immunol. 2001,166, 952–958.
86. Macian, F.; Im, S.H.; Garcia-Cozar, F.J.; Rao, A. T cell anergy. Curr. Opin. Immunol. 2004, 16, 209–216.
87. Kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 2002, 168, 2729–2736.
88. Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26, 677–704.
89. Fife, B.T.; Pauken, K.E. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. NY Acad. Sci. 2011, 1217, 45–59.
90. Quigley, M.; Pereyra, F.; Nilsson, B.; Porichis, F.; Fonseca, C.; Eichbaum, Q.; Julg, B.; Jesneck, J.L.; Brosnahan, K.; Imam, S.; et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med. 2010, 16, 1147–1151.
91. Murphy, T.L.; Tussiwand, R.; Murphy, K.M. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat. Rev. Immunol. 2013, 13, 499–509.
92. Levy, D.E.; Kessler, D.S.; Pine, R.; Darnell, J.E., Jr. Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro. Genes Dev. 1989, 3, 1362–1371.
93. Kao, C.; Oestreich, K.J.; Paley, M.A.; Crawford, A.; Angelosanto, J.M.; Ali, M.A.; Intlekofer, A.M.; Boss, J.M.; Reiner, S.L.; Weinmann, A.S.; et al. Transcription factor t-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 2011, 12, 663–671.
94. Staron, M.M.; Gray, S.M.; Marshall, H.D.; Parish, I.A.; Chen, J.H.; Perry, C.J.; Cui, G.; Li, M.O.; Kaech, S.M. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity 2014, 41, 802–814.
95. Shin, H.; Blackburn, S.D.; Intlekofer, A.M.; Kao, C.; Angelosanto, J.M.; Reiner, S.L.; Wherry, E.J. A role for the transcriptional repressor BLIMP-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 2009, 31, 309–320.
96. Oestreich, K.J.; Yoon, H.; Ahmed, R.; Boss, J.M. Nfatc1 regulates PD-1 expression upon T cell activation. J. Immunol. 2008, 181, 4832–4839.
97. Youngblood, B.; Oestreich, K.J.; Ha, S.J.; Duraiswamy, J.; Akondy, R.S.; West, E.E.; Wei, Z.; Lu, P.; Austin, J.W.; Riley, J.L.; et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 2011, 35, 400–412.
98. Fehr, T.; Lucas, C.L.; Kurtz, J.; Onoe, T.; Zhao, G.; Hogan, T.; Vallot, C.; Rao, A.; Sykes, M. A CD8 T cell-intrinsic role for the calcineurin-NFAT pathway for tolerance induction in vivo. Blood2010, 115, 1280–1287.
99. Heissmeyer, V.; Macian, F.; Im, S.H.; Varma, R.; Feske, S.; Venuprasad, K.; Gu, H.; Liu, Y.C.; Dustin, M.L.; Rao, A. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat. Immunol. 2004, 5, 255–265.
100. Macian, F. NFAT proteins: Key regulators of T cell development and function. Nat. Rev. Immunol.2005, 5, 472–484.
101. Thomas, R.M.; Chunder, N.; Chen, C.; Umetsu, S.E.; Winandy, S.; Wells, A.D. Ikaros enforces the costimulatory requirement for IL2 gene expression and is required for anergy induction in CD4+ T lymphocytes. J. Immunol. 2007, 179, 7305–7315.
102. Baine, I.; Basu, S.; Ames, R.; Sellers, R.S.; Macian, F. Helios induces epigenetic silencing of IL2 gene expression in regulatory T cells. J. Immunol. 2013, 190, 1008–1016.
103. Bandyopadhyay, S.; Dure, M.; Paroder, M.; Soto-Nieves, N.; Puga, I.; Macian, F. Interleukin 2 gene transcription is regulated by ikaros-induced changes in histone acetylation in anergic T cells. Blood 2007, 109, 2878–2886.
104. O’Brien, S.; Thomas, R.M.; Wertheim, G.B.; Zhang, F.; Shen, H.; Wells, A.D. Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production. J. Immunol. 2014,192, 5118–5129.
105. Paley, M.A.; Kroy, D.C.; Odorizzi, P.M.; Johnnidis, J.B.; Dolfi, D.V.; Barnett, B.E.; Bikoff, E.K.; Robertson, E.J.; Lauer, G.M.; Reiner, S.L.; et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012, 338, 1220–1225.
106. Wherry, E.J. T cell exhaustion. Nat. Immunol. 2011, 12, 492–499.
107. Zajac, A.J.; Blattman, J.N.; Murali-Krishna, K.; Sourdive, D.J.; Suresh, M.; Altman, J.D.; Ahmed, R. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 1998, 188, 2205–2213.
108. Gallimore, A.; Glithero, A.; Godkin, A.; Tissot, A.C.; Pluckthun, A.; Elliott, T.; Hengartner, H.; Zinkernagel, R. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 1998, 187, 1383–1393.
109. Doering, T.A.; Crawford, A.; Angelosanto, J.M.; Paley, M.A.; Ziegler, C.G.; Wherry, E.J. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 2012, 37, 1130–1144.
110. Rangachari, M.; Zhu, C.; Sakuishi, K.; Xiao, S.; Karman, J.; Chen, A.; Angin, M.; Wakeham, A.; Greenfield, E.A.; Sobel, R.A.; et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat. Med. 2012, 18, 1394–1400.
111. Larsson, M.; Shankar, E.M.; Che, K.F.; Saeidi, A.; Ellegard, R.; Barathan, M.; Velu, V.; Kamarulzaman, A. Molecular signatures of T cell inhibition in HIV-1 infection. Retrovirology 2013.
112. Angelosanto, J.M.; Wherry, E.J. Transcription factor regulation of CD8+ T cell memory and exhaustion. Immunol. Rev. 2010, 236, 167–175.
113. Hess Michelini, R.; Doedens, A.L.; Goldrath, A.W.; Hedrick, S.M. Differentiation of CD8 memory T cells depends on FoxO1. J. Exp. Med. 2013, 210, 1189–1200.
114. Kim, M.V.; Ouyang, W.; Liao, W.; Zhang, M.Q.; Li, M.O. The transcription factor FoxO1 controls central-memory CD8+ T cell responses to infection. Immunity 2013, 39, 286–297.
115. Sullivan, J.A.; Kim, E.H.; Plisch, E.H.; Suresh, M. FoxO3 regulates the CD8 T cell response to a chronic viral infection. J. Virol. 2012, 86, 9025–9034.
116. Tzelepis, F.; Joseph, J.; Haddad, E.K.; Maclean, S.; Dudani, R.; Agenes, F.; Peng, S.L.; Sekaly, R.P.; Sad, S. Intrinsic role of foxO3a in the development of CD8+ T cell memory. J. Immunol.2013, 190, 1066–1075.
117. Togher, S.; Larange, A.; Schoenberger, S.P.; Feau, S. Foxo3 is a negative regulator of primary CD8+ T cell expansion but not of memory formation. Immunol. Cell Biol. 2015, 93, 120–125.
118. Crespo, J.; Sun, H.; Welling, T.H.; Tian, Z.; Zou, W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 2013, 25, 214–221.
119. Klebanoff, C.A.; Gattinoni, L.; Restifo, N.P. CD8+ T cell memory in tumor immunology and immunotherapy. Immunol. Rev. 2006, 211, 214–224.
120. John, S.A.; Garrett-Sinha, L.A. Blimp1: A conserved transcriptional repressor critical for differentiation of many tissues. Exp. Cell Res. 2009, 315, 1077–1084.
121. Martins, G.A.; Cimmino, L.; Shapiro-Shelef, M.; Szabolcs, M.; Herron, A.; Magnusdottir, E.; Calame, K. Transcriptional repressor BLIMP-1 regulates T cell homeostasis and function. Nat. Immunol. 2006, 7, 457–465.
122. Kallies, A.; Hawkins, E.D.; Belz, G.T.; Metcalf, D.; Hommel, M.; Corcoran, L.M.; Hodgkin, P.D.; Nutt, S.L. Transcriptional repressor BLIMP-1 is essential for T cell homeostasis and self-tolerance. Nat. Immunol. 2006, 7, 466–474.
123. Rutishauser, R.L.; Martins, G.A.; Kalachikov, S.; Chandele, A.; Parish, I.A.; Meffre, E.; Jacob, J.; Calame, K.; Kaech, S.M. Transcriptional repressor BLIMP-1 promotes CD8+ T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity 2009,31, 296–308.
124. Kallies, A.; Xin, A.; Belz, G.T.; Nutt, S.L. BLIMP-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity 2009, 31, 283–295.
125. Cimmino, L.; Martins, G.A.; Liao, J.; Magnusdottir, E.; Grunig, G.; Perez, R.K.; Calame, K.L. BLIMP-1 attenuates Th1 differentiation by repression of Ifng, tbx21, and bcl6 gene expression. J. Immunol. 2008, 181, 2338–2347.
126. Martins, G.A.; Cimmino, L.; Liao, J.; Magnusdottir, E.; Calame, K. Blimp-1 directly represses IL2 and the IL2 activator Fos, attenuating T cell proliferation and survival. J. Exp. Med. 2008, 205, 1959–1965.
127. Ji, Y.; Pos, Z.; Rao, M.; Klebanoff, C.A.; Yu, Z.; Sukumar, M.; Reger, R.N.; Palmer, D.C.; Borman, Z.A.; Muranski, P.; et al. Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat. Immunol. 2011, 12, 1230–1237.
128. Lu, P.; Youngblood, B.A.; Austin, J.W.; Mohammed, A.U.; Butler, R.; Ahmed, R.; Boss, J.M. Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J. Exp. Med. 2014, 211, 515–527.
129. Crotty, S.; Johnston, R.J.; Schoenberger, S.P. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat. Immunol. 2010, 11, 114–120.
130. Ancelin, K.; Lange, U.C.; Hajkova, P.; Schneider, R.; Bannister, A.J.; Kouzarides, T.; Surani, M.A. Blimp1 associates with prmt5 and directs histone arginine methylation in mouse germ cells. Nat. Cell Biol. 2006, 8, 623–630.
131. Yu, J.; Angelin-Duclos, C.; Greenwood, J.; Liao, J.; Calame, K. Transcriptional repression by Blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol. Cell. Biol. 2000, 20, 2592–2603.
132. Gyory, I.; Wu, J.; Fejer, G.; Seto, E.; Wright, K.L. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat. Immunol. 2004, 5, 299–308.
133. Su, S.T.; Ying, H.Y.; Chiu, Y.K.; Lin, F.R.; Chen, M.Y.; Lin, K.I. Involvement of histone demethylase LSD1 in Blimp-1-mediated gene repression during plasma cell differentiation. Mol. Cell. Biol. 2009, 29, 1421–1431.
134. Heng, T.S.; Painter, M.W.; Immunological Genome Project, C. The immunological genome project: Networks of gene expression in immune cells. Nat. Immunol. 2008, 9, 1091–1094.
135. Schoenborn, J.R.; Dorschner, M.O.; Sekimata, M.; Santer, D.M.; Shnyreva, M.; Fitzpatrick, D.R.; Stamatoyannopoulos, J.A.; Wilson, C.B. Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon-gamma. Nat. Immunol. 2007, 8, 732–742.
136. Creyghton, M.P.; Cheng, A.W.; Welstead, G.G.; Kooistra, T.; Carey, B.W.; Steine, E.J.; Hanna, J.; Lodato, M.A.; Frampton, G.M.; Sharp, P.A.; et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 2010, 107, 21931–21936.
137. Rada-Iglesias, A.; Bajpai, R.; Swigut, T.; Brugmann, S.A.; Flynn, R.A.; Wysocka, J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011, 470, 279–283.
138. Ooi, S.K.; Qiu, C.; Bernstein, E.; Li, K.; Jia, D.; Yang, Z.; Erdjument-Bromage, H.; Tempst, P.; Lin, S.P.; Allis, C.D.; et al. DNMT3l connects unmethylated lysine 4 of histone H3 to de novomethylation of DNA. Nature 2007, 448, 714–717.
139. Yu, Q.; Thieu, V.T.; Kaplan, M.H. Stat4 limits DNA methyltransferase recruitment and DNA methylation of the IL-18ralpha gene during Th1 differentiation. EMBO J. 2007, 26, 2052–2060.
140. Parish, I.A.; Rao, S.; Smyth, G.K.; Juelich, T.; Denyer, G.S.; Davey, G.M.; Strasser, A.; Heath, W.R. The molecular signature of CD8+ T cells undergoing deletional tolerance. Blood 2009, 113, 4575–4585.
141. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550.
142. Mootha, V.K.; Lindgren, C.M.; Eriksson, K.F.; Subramanian, A.; Sihag, S.; Lehar, J.; Puigserver, P.; Carlsson, E.; Ridderstrale, M.; Laurila, E.; et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003,34, 267–273.
143. Huang da, W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using david bioinformatics resources. Nat. Protoc. 2009, 4, 44–57.
144. Huang da, W.; Sherman, B.T.; Lempicki, R.A. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucl. Acids Res. 2009, 37, 1–13.
145. Chang, J.T.; Nevins, J.R. Gather: A systems approach to interpreting genomic signatures. Bioinformatics 2006, 22, 2926–2933.
146. Sakuishi, K.; Apetoh, L.; Sullivan, J.M.; Blazar, B.R.; Kuchroo, V.K.; Anderson, A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207, 2187–2194.
147. Chemnitz, J.M.; Parry, R.V.; Nichols, K.E.; June, C.H.; Riley, J.L. SHP-1 AND SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 2004, 173, 945–954.
148. Lee, J.; Su, E.W.; Zhu, C.; Hainline, S.; Phuah, J.; Moroco, J.A.; Smithgall, T.E.; Kuchroo, V.K.; Kane, L.P. Phosphotyrosine-dependent coupling of Tim-3 to T cell receptor signaling pathways. Mol. Cell. Biol. 2011, 31, 3963–3974.
149. Ferris, R.L.; Lu, B.; Kane, L.P. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J. Immunol. 2014, 193, 1525–1530.
150. Agnellini, P.; Wolint, P.; Rehr, M.; Cahenzli, J.; Karrer, U.; Oxenius, A. Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection. Proc. Natl. Acad. Sci. USA 2007, 104, 4565–4570.
151. Martinez, G.J.; Pereira, R.M.; Aijo, T.; Kim, E.Y.; Marangoni, F.; Pipkin, M.E.; Togher, S.; Heissmeyer, V.; Zhang, Y.C.; Crotty, S.; et al. The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells. Immunity 2015, 42, 265–278.
152. Blackburn, S.D.; Shin, H.; Freeman, G.J.; Wherry, E.J. Selective expansion of a subset of exhausted CD8 T cells by alphapd-l1 blockade. Proc. Natl. Acad. Sci. USA 2008, 105, 15016–15021.
153. Buggert, M.; Tauriainen, J.; Yamamoto, T.; Frederiksen, J.; Ivarsson, M.A.; Michaelsson, J.; Lund, O.; Hejdeman, B.; Jansson, M.; Sonnerborg, A.; et al. T-bet and eomes are differentially linked to the exhausted phenotype of CD8+ T cells in hiv infection. PLoS Pathog. 2014, 10, e1004251.
154. Zhu, Y.; Ju, S.; Chen, E.; Dai, S.; Li, C.; Morel, P.; Liu, L.; Zhang, X.; Lu, B. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J. Immunol. 2010,185, 3174–3183.
155. Song, C.; Sadashivaiah, K.; Furusawa, A.; Davila, E.; Tamada, K.; Banerjee, A. Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. Oncoimmunology 2014, 3, e27680.
156. Berrien-Elliott, M.M.; Yuan, J.; Swier, L.E.; Jackson, S.R.; Chen, C.L.; Donlin, M.J.; Teague, R.M. Checkpoint blockade immunotherapy relies on T-bet but not eomes to induce effector function in tumor-infiltrating CD8+ T cells. Cancer Immunol. Res. 2015, 3, 116–124.
157. Zitvogel, L.; Kroemer, G. Targeting foxp1 for reinstating anticancer immunosurveillance. Immunity 2014, 41, 345–347.
158. Zhang, N.; Bevan, M.J. Tgf-beta signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nat. Immunol. 2012, 13, 667–673.
159. Malhotra, N.; Kang, J. Smad regulatory networks construct a balanced immune system. Immunology 2013, 139, 1–10.
160. Tinoco, R.; Alcalde, V.; Yang, Y.; Sauer, K.; Zuniga, E.I. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 2009, 31, 145–157.
161. Garidou, L.; Heydari, S.; Gossa, S.; McGavern, D.B. Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection. J. Virol. 2012, 86, 7060–7071.
162. Shi, Y.; Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113, 685–700.
163. Mokrani, M.; Klibi, J.; Bluteau, D.; Bismuth, G.; Mami-Chouaib, F. Smad and nfat pathways cooperate to induce CD103 expression in human CD8 T lymphocytes. J. Immunol. 2014, 192, 2471–2479.
164. Stephen, T.L.; Rutkowski, M.R.; Allegrezza, M.J.; Perales-Puchalt, A.; Tesone, A.J.; Svoronos, N.; Nguyen, J.M.; Sarmin, F.; Borowsky, M.E.; Tchou, J.; et al. Transforming growth factor beta-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity 2014, 41, 427–439.
165. Feng, X.; Wang, H.; Takata, H.; Day, T.J.; Willen, J.; Hu, H. Transcription factor FoxP1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat. Immunol. 2011, 12, 544–550.
166. Skon, C.N.; Jameson, S.C. Fox factors fight over T cell quiescence. Nat. Immunol. 2011, 12, 522–524.
167. Chapman, N.M.; Chi, H. mTOR links environmental signals to T cell fate decisions. Front. Immunol. 2014.
168. Sinclair, L.V.; Finlay, D.; Feijoo, C.; Cornish, G.H.; Gray, A.; Ager, A.; Okkenhaug, K.; Hagenbeek, T.J.; Spits, H.; Cantrell, D.A. Phosphatidylinositol-3-oh kinase and nutrient-sensing mtor pathways control t lymphocyte trafficking. Nat. Immunol. 2008, 9, 513–521.
169. Sukumar, M.; Liu, J.; Ji, Y.; Subramanian, M.; Crompton, J.G.; Yu, Z.; Roychoudhuri, R.; Palmer, D.C.; Muranski, P.; Karoly, E.D.; et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Investig. 2013, 123, 4479–4488.
170. Kumar, V.; Gabrilovich, D.I. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 2014, 143, 512–519.
171. Palazon, A.; Martinez-Forero, I.; Teijeira, A.; Morales-Kastresana, A.; Alfaro, C.; Sanmamed, M.F.; Perez-Gracia, J.L.; Penuelas, I.; Hervas-Stubbs, S.; Rouzaut, A.; et al. The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1bb) for immunotherapy. Cancer Discov. 2012, 2, 608–623.
172. Yonezawa, A.; Dutt, S.; Chester, C.; Kim, J.; Kohrt, H.E. Boosting cancer immunotherapy with anti-CD137 antibody therapy. Clin. Cancer Res. 2015.
173. Doedens, A.L.; Phan, A.T.; Stradner, M.H.; Fujimoto, J.K.; Nguyen, J.V.; Yang, E.; Johnson, R.S.; Goldrath, A.W. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat. Immunol. 2013, 14, 1173–1182.
174. Berezhnoy, A.; Castro, I.; Levay, A.; Malek, T.R.; Gilboa, E. Aptamer-targeted inhibition of mtor in T cells enhances antitumor immunity. J. Clin. Investig. 2014, 124, 188–197.
175. Araki, K.; Turner, A.P.; Shaffer, V.O.; Gangappa, S.; Keller, S.A.; Bachmann, M.F.; Larsen, C.P.; Ahmed, R. Mtor regulates memory CD8 T cell differentiation. Nature 2009, 460, 108–112.
176. Joshi, N.S.; Cui, W.; Chandele, A.; Lee, H.K.; Urso, D.R.; Hagman, J.; Gapin, L.; Kaech, S.M. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of t-bet transcription factor. Immunity 2007, 27, 281–295.
177. Zhou, X.; Yu, S.; Zhao, D.M.; Harty, J.T.; Badovinac, V.P.; Xue, H.H. Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity 2010, 33, 229–240.
178. Pearce, E.L.; Walsh, M.C.; Cejas, P.J.; Harms, G.M.; Shen, H.; Wang, L.S.; Jones, R.G.; Choi, Y. Enhancing CD8 T cell memory by modulating fatty acid metabolism. Nature 2009, 460, 103–107.
179. Jeannet, G.; Boudousquie, C.; Gardiol, N.; Kang, J.; Huelsken, J.; Held, W. Essential role of the Wnt pathway effector TCF-1 for the establishment of functional CD8 T cell memory. Proc. Natl. Acad. Sci. USA 2010, 107, 9777–9782.
180. Keefe, A.D.; Pai, S.; Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 2010, 9, 537–550.
181. Delgoffe, G.M.; Kole, T.P.; Zheng, Y.; Zarek, P.E.; Matthews, K.L.; Xiao, B.; Worley, P.F.; Kozma, S.C.; Powell, J.D. The mtor kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30, 832–844.
182. Dassie, J.P.; Liu, X.Y.; Thomas, G.S.; Whitaker, R.M.; Thiel, K.W.; Stockdale, K.R.; Meyerholz, D.K.; McCaffrey, A.P.; McNamara, J.O., II; Giangrande, P.H. Systemic administration of optimized aptamer-sirna chimeras promotes regression of psma-expressing tumors. Nat. Biotechnol. 2009, 27, 839–849.
183. Ni, X.; Zhang, Y.; Ribas, J.; Chowdhury, W.H.; Castanares, M.; Zhang, Z.; Laiho, M.; DeWeese, T.L.; Lupold, S.E. Prostate-targeted radiosensitization via aptamer-shrna chimeras in human tumor xenografts. J. Clin. Investig. 2011, 121, 2383–2390.
184. Pastor, F.; Kolonias, D.; Giangrande, P.H.; Gilboa, E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mrna decay. Nature 2010, 465, 227–230.
185. Pastor, F.; Kolonias, D.; McNamara, J.O., 2nd; Gilboa, E. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol. Ther. 2011, 19, 1878–1886.
186. Gattinoni, L.; Klebanoff, C.A.; Restifo, N.P. Paths to stemness: Building the ultimate antitumour T cell. Nat. Rev. Cancer 2012, 12, 671–684.
187. Gattinoni, L.; Lugli, E.; Ji, Y.; Pos, Z.; Paulos, C.M.; Quigley, M.F.; Almeida, J.R.; Gostick, E.; Yu, Z.; Carpenito, C.; et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 2011, 17, 1290–1297.
188. Zhao, D.M.; Yu, S.; Zhou, X.; Haring, J.S.; Held, W.; Badovinac, V.P.; Harty, J.T.; Xue, H.H. Constitutive activation of Wnt signaling favors generation of memory CD8 T cells. J. Immunol.2010, 184, 1191–1199.
189. Kalos, M.; Levine, B.L.; Porter, D.L.; Katz, S.; Grupp, S.A.; Bagg, A.; June, C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011.
190. Rosenberg, S.A.; Yang, J.C.; Sherry, R.M.; Kammula, U.S.; Hughes, M.S.; Phan, G.Q.; Citrin, D.E.; Restifo, N.P.; Robbins, P.F.; Wunderlich, J.R.; et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin. Cancer Res. 2011, 17, 4550–4557.
191. Robbins, P.F.; Dudley, M.E.; Wunderlich, J.; El-Gamil, M.; Li, Y.F.; Zhou, J.; Huang, J.; Powell, D.J., Jr.; Rosenberg, S.A. Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 2004, 173, 7125–7130.
192. Pule, M.A.; Savoldo, B.; Myers, G.D.; Rossig, C.; Russell, H.V.; Dotti, G.; Huls, M.H.; Liu, E.; Gee, A.P.; Mei, Z.; et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 2008, 14, 1264–1270.
193. Gattinoni, L.; Klebanoff, C.A.; Restifo, N.P. Pharmacologic induction of CD8+ T cell memory: Better living through chemistry. Sci. Transl. Med. 2009.
194. Zhou, P.; Shaffer, D.R.; Alvarez Arias, D.A.; Nakazaki, Y.; Pos, W.; Torres, A.J.; Cremasco, V.; Dougan, S.K.; Cowley, G.S.; Elpek, K.; et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 2014, 506, 52–57.
195. Barrangou, R.; Birmingham, A.; Wiemann, S.; Beijersbergen, R.L.; Hornung, V.; Smith, A. Advances in CRISPR-Cas9 genome engineering: Lessons learned from RNA interference. Nucl. Acids Res. 2015, 43, 3407–3419.
196. Zheng, S.; Moehlenbrink, J.; Lu, Y.C.; Zalmas, L.P.; Sagum, C.A.; Carr, S.; McGouran, J.F.; Alexander, L.; Fedorov, O.; Munro, S.; et al. Arginine methylation-dependent reader-writer interplay governs growth control by e2f-1. Mol. Cell 2013, 52, 37–51.
197. Dey, S.S.; Kester, L.; Spanjaard, B.; Bienko, M.; van Oudenaarden, A. Integrated genome and transcriptome sequencing of the same cell. Nat. Biotechnol. 2015, 33, 285–289.